ALTJ V35Gy above 50% tripled lymphedema risk after breast radiotherapy
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Combined high-dose and high-LET exposure around breast implants was associated with severe capsular contracture after proton postmastectomy radiotherapy.
Modeling relationships between CT radiomic features improved distant-metastasis prediction over conventional radiomics across independent head and neck cancer cohorts.
Multi-RBE carbon-ion optimization increased near-minimum GTV LET by 29.2% while maintaining conventional dose coverage and interfraction robustness.
A model integrating planning CT, 3D dose and tumor contours achieved strong external prediction of distant metastasis but weaker local-recurrence performance.
Robust optimization improved target coverage with less lung-dose penalty than margin expansion, while density override was particularly useful for solid tumors.
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
Despite successful simulation, 31.7% required DIBH gate modification or conversion to free breathing during abdominal radiotherapy.
Combined radiomics, foundation-model and clinical features predicted grade ≥2 radiation proctitis with 0.865 AUC on an independent imaging device.
D95% and D98% PTV prescriptions produced substantial interpatient variability, while GTV- and ITV-based median or mean doses were more accurate.
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.
Administrative burden and staffing concerns were widespread, while reimbursement dominated private-practice concerns and unstable research funding dominated physician-scientist concerns.
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
A DAHANCA 35 patient decision aid was feasible and acceptable, but its value depended strongly on clinician introduction and engagement.
Emission-only PET synthesis produced 0.72% SUVmax bias and 99.2% contrast recovery in an independent NSCLC test cohort.